The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial

Author:

Winthrop Kevin L.1,Wouters Ann G.2,Choy Ernest H.3,Soma Koshika2,Hodge Jennifer A.2,Nduaka Chudy I.4,Biswas Pinaki2,Needle Elie5,Passador Sherry2,Mojcik Christopher F.2,Rigby William F.6

Affiliation:

1. Oregon Health and Science University; Portland

2. Pfizer Inc; New York New York

3. Cardiff University School of Medicine; Cardiff UK

4. Chudy I. Nduaka, DVM, PhD: Pfizer Inc; Collegeville Pennsylvania

5. Pfizer Inc; Pearl River New York

6. Geisel School of Medicine at Dartmouth; Lebanon New Hampshire

Funder

Pfizer

This study was sponsored by Pfizer Inc.

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Reference31 articles.

1. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP);Harpaz;MMWR Recomm Rep,2008

2. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination;Yun;Arthritis Rheumatol,2016

3. Safety profile of baricitinib in patients with active RA: integrated analysis [abstract];Smolen;Ann Rheum Dis,2016

4. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis;Jung;Leuk Lymphoma,2015

5. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies;Fleischmann;Int J Rheum Dis,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3